EU signs joint procurement deal with Spain’s HIPRA for COVID vaccines

Euractiv | Aug 3, 2022 at 9:00 AM
  • The European Commission said on Tuesday (2 August) that it had signed a joint procurement contract with Spanish pharmaceutical firm HIPRA for the supply of its protein COVID-19 vaccine.
  • The HIPRA bivalent recombinant protein vaccine is being developed as a booster dose in previously immunised persons 16 years and older.
  • It uses a recombinant protein like that of U.S.-based drugmaker Novavax.